aidsmap news story
Eight years after it started, the final results of a large French study that offered a choice of daily or event-driven oral PrEP (using tenofovir disoproxil/emtricitabine) were presented at CROI 2026.
The Prévenir Study enrolled over 3200 people, most of them gay or bisexual cisgender men, at 26 sites in the Paris region.
If there was one message coming from the eight years of Prévenir, Professor Molina said, it was that both daily and on-demand oral PrEP were safe and effective in the study population. However, there is clearly a need to implement PrEP in France in gay and bisexual men and transgender women born abroad and other populations at risk of HIV acquisition.
Read the full news story here.
View all aidsmap reports from CROI 2026
SEE ALSO:
View all HIV i-Base reports from CROI 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.